Despite these limitations, ctDNA‐based detection is increasingly incorporated into clinical guidelines as a practical tool for guiding EGFR‐TKI sequencing in NSCLC, and our findings further support its value for identifying actionable resistance mutations and stratifying patients for osimertinib therapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.